Medicinal Products

Ximluci

The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.

Name	Ximluci
Active Substance	ranibizumab
Prescription	Medicinal product subject to medical prescription
Type of prescription	ograničeni recept
Distribution	Supply through pharmacies (community)
ATC Code	S01LA04
Marketing status	stavljeno u promet
Shortage status	nema nestašice
Summary of product characteristics (SmPC), labelling and package leaflet (PL)	download
Link to the European Medicines Agency's (EMA) product information	download
Link to the European Commission's (EC) decisions	download
Educational materials for patients / caregivers	Vodic za bolesnike dijabetička retinopatija ili dijabetički makularni edem, verzija 1 Vodič za bolesnike dijabetički makularni edem (DME), verzija 4 Vodič za bolesnike neovaskularizacija žilnice (CNV), verzija 4 Vodič za bolesnike neovaskularna, senilna, makularna degeneracija (AMD), verzija 4 Vodič za bolesnike začepljenje vene u pozadini mrežnice, verzija 4 Audio vodič za bolesnike - dijabetička retinopatija ili dijabetički makularni edem, verzija 1 Audio vodič za bolesnike - dijabetički makularni edem (DME), verzija 4 Audio vodič za bolesnike - neovaskularizacija žilnice (CNV), verzija 4 Audio vodič za bolesnike - neovaskularna, senilna, makularna degeneracija (AMD), verzija 4 Audio vodič za bolesnike - začepljenje vene u pozadini mrežnice, verzija 4

Packaging

Back

For Patients and Public

For Health Care Professionals

For Industry Representatives